Literature DB >> 24783044

2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.

P Beck-Peccoz1, A Lania2, A Beckers3, K Chatterjee4, J-L Wemeau5.   

Abstract

Hyperthyroidism is mainly due to autoimmune thyroid disorders or toxic goiter, and very rarely to the presence of thyrotropin (TSH)-secreting pituitary adenomas (TSHomas). These tumors are characterized by high levels of circulating free thyroid hormones (FT4 and FT3) in the presence of nonsuppressed serum TSH concentrations. Failure to correctly diagnose TSHomas may result in inappropriate thyroid ablation, which results in a significant increase of pituitary tumor mass. The diagnosis is mainly achieved by measuring TSH after T3 suppression and TRH stimulation tests. These dynamic tests, together with pituitary imaging and genetic testing are useful in distinguishing TSHomas from the syndromes of resistance to thyroid hormone action. The treatment of choice is surgery. In cases of surgical failure, somatostatin analogs have been found to be effective in normalizing TSH secretion in more than 90% of patients.

Entities:  

Keywords:  Central hyperthyroidism; Resistance to thyroid hormones; Somatostatin analogs; Thyrotropin; Thyrotropin-secreting pituitary adenoma; Transsphenoidal surgery

Year:  2013        PMID： 24783044      PMCID： PMC3821512          DOI： 10.1159/000351007

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN： 2235-0640


  32 in total

1.  Incidence of pituitary adenomas in Northern Finland in 1992-2007.

Authors:  Antti Raappana; John Koivukangas; Tapani Ebeling; Tapio Pirilä
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes.

Authors:  Q Dong; F Brucker-Davis; B D Weintraub; R C Smallridge; F E Carr; J Battey; A M Spiegel; A Shenker
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

3.  An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors.

Authors:  N J Gittoes; C J McCabe; J Verhaeg; M C Sheppard; J A Franklyn
Journal:  Thyroid       Date:  1998-01       Impact factor: 6.568

4.  Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH".

Authors:  M C Gershengorn; B D Weintraub
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

5.  Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.

Authors:  Deborah Mannavola; Luca Persani; Guia Vannucchi; Maddalena Zanardelli; Laura Fugazzola; Uberta Verga; Marco Facchetti; Paolo Beck-Peccoz
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

Review 6.  Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment.

Authors:  N Sanno; A Teramoto; R Y Osamura
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

7.  Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types.

Authors:  S Corbetta; A Pizzocaro; M Peracchi; P Beck-Peccoz; G Faglia; A Spada
Journal:  Clin Endocrinol (Oxf)       Date:  1997-11       Impact factor: 3.478

Review 8.  Pituitary tumours: TSH-secreting adenomas.

Authors:  Paolo Beck-Peccoz; Luca Persani; Deborah Mannavola; Irene Campi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

9.  Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Gordon H Guyatt; Deborah J Cook; Roman Jaeschke; Stephen G Pauker; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478
View more
  42 in total

1.  Treatment of pituitary tumours in 2014: Advances in therapy of adenomas secreting GH, ACTH and TSH.

Authors:  Annamaria Colao
Journal:  Nat Rev Endocrinol       Date:  2014-12-23       Impact factor: 43.330

2.  Characteristics of patients with late manifestation of resistance thyroid hormone syndrome: a single-center experience.

Authors:  Rulai Han; Lei Ye; Xiaohua Jiang; Xiaoyi Zhou; Cyrielle Billon; Wenyue Guan; Karine Gauthier; Weiyuan Fang; Weiqing Wang; Jacques Samarut; Guang Ning
Journal:  Endocrine       Date:  2015-06-04       Impact factor: 3.633

Review 3.  A 2019 update on TSH-secreting pituitary adenomas.

Authors:  P Beck-Peccoz; C Giavoli; A Lania
Journal:  J Endocrinol Invest       Date:  2019-06-07       Impact factor: 4.256

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism.

Authors:  Mahdi Kamoun; Michèle d'Herbomez; Christine Lemaire; Armelle Fayard; Rachel Desailloud; Damien Huglo; Jean-Louis Wemeau
Journal:  Eur Thyroid J       Date:  2013-11-20

Review 6.  Mutational Landscape of Resistance to Thyroid Hormone Beta (RTHβ).

Authors:  Paola Concolino; Alessandra Costella; Rosa Maria Paragliola
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

7.  Supra-physiological rhGH administration induces gender-related differences in the hypothalamus-pituitary-thyroid (HPT) axis in healthy individuals.

Authors:  P Sgrò; M Sansone; A Parisi; A Sartorio; A Sansone; F Romanelli; A Lenzi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2016-05-26       Impact factor: 4.256

Review 8.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

9.  Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center.

Authors:  D M Nazato; J Abucham
Journal:  J Endocrinol Invest       Date:  2017-10-11       Impact factor: 4.256

10.  Status and clinical and radiological predictive factors of presurgical anterior pituitary function in pituitary adenomas. Study of 232 patients.

Authors:  Marta Araujo-Castro; Eider Pascual-Corrales; Alberto Acitores Cancela; Sara García Duque; Luis Ley Urzaiz; Víctor Rodríguez Berrocal
Journal:  Endocrine       Date:  2020-08-12       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.